Pancreatic Cancer Resectable Clinical Trial
Official title:
Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study
| Verified date | July 2022 |
| Source | Ruijin Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.
| Status | Completed |
| Enrollment | 226 |
| Est. completion date | September 13, 2021 |
| Est. primary completion date | August 3, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 34 Years to 84 Years |
| Eligibility | Inclusion Criteria: - Radically resected pancreatic adenocarcinoma (stage I-III) - Resected tumor tissues and matched blood cells available - Signed informed consent Exclusion Criteria: - Pancreatic cancer except pancreatic adenocarcinoma - Non-radical resection |
| Country | Name | City | State |
|---|---|---|---|
| China | Ruijin Hospital | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| BAIYONG SHEN | GeneCast Biotechnology Co., Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Disease-free survival (DFS) | Comparison of DFS between patients with specific HLA-I genotypes or not | 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06368063 -
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
|
Phase 4 | |
| Not yet recruiting |
NCT06375928 -
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)
|
N/A | |
| Recruiting |
NCT06388967 -
Pancreatic Cancer Detection Consortium
|
||
| Recruiting |
NCT05287165 -
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
|
Early Phase 1 | |
| Not yet recruiting |
NCT06287749 -
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
|
||
| Recruiting |
NCT03977233 -
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04736043 -
Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
|
||
| Completed |
NCT04224402 -
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
|
Phase 2 | |
| Terminated |
NCT03344172 -
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05479708 -
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
|
||
| Not yet recruiting |
NCT05637567 -
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
|
Phase 2 | |
| Recruiting |
NCT05181605 -
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
|
Phase 2/Phase 3 |